Hi there Maxkieh,
What timeframe was this target price?
Although I love ARX and its management, the company is not well supported/ known by the ASX investors. Perhaps because it is a NZ company it doesn't attract the same fan base that PNV does.
At $11.00 per share, this would equate to a valuation of over $3.00b for ARX. This is unlikely in the next couple of years. I would love to be proved wrong though. Even PNV currently only has a market cap of $1.86b on similar sales revenue.
PNV forward sales revenue growth and gross margins are superior to ARX.
Bell Potter offer a more realistic price target of around $2.10 for ARX.
News: ARX Aroa Biosurgery Posts FY22 Product Sales Guidance Of $30M-33M, page-7
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ARX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
59.8¢ |
Change
-0.003(0.42%) |
Mkt cap ! $205.6M | |||
| Open | High | Low | Value | Volume |
| 61.0¢ | 61.0¢ | 58.0¢ | $80.65K | 134.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 24656 | 59.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 60.0¢ | 13000 | 2 |
View Market Depth
| Last trade - 15.47pm 28/06/2024 (20 minute delay) ? |
| ARX (ASX) Chart |